12:00 AM
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Graspa: Phase II data

An open-label, dose-escalation, French Phase II trial in 30 patients aged 55 and older with newly diagnosed Philadelphia chromosome-negative (Ph-) ALL showed that 2 infusions of Graspa given during standard induction chemotherapy led to target asparagine depletion for >=7 days, a component of the primary endpoint, in 85% of patients receiving the 100 IU/kg dose (n=13) and in 71% of patients receiving the 150 IU/kg dose (n=14). Only 3 patients received 50 IU/kg Graspa due to insufficient serum asparagine depletion. Median EFS was 11.8 months for 100 IU/kg Graspa and...

Read the full 427 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >